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combined treatments, an operation remains a suitable
therapeutic tool, owing to the limited efficacy of both
radiotherapy and systemic chemotherapy. However, it
has been stressed that an operation, regardless of
whether pleuropneumonectomy or pleurectomy/decor-
tication is performed, basically represents a cytoreduc-
tive procedure, requiring adjuvant therapies.2 In this
setting, malignant mesothelioma appears to be an ideal
model for the application of regional chemotherapy
because of its tendency to remain, at least initially, a
local disease.3 The feasibility and safety of intrapleural
cisplatin-based chemotherapy has already been demon-
strated4 with different therapeutic approaches. Normo-
thermic intrapleural antineoplastic instillation has been
used either after an operation4,5 or as a primary treat-
ment.6 Hyperthermic pleural space antineoplastic per-
fusion has been used in patients who did not undergo an
T he presently available single-modality or bimodalitytherapeutic options for malignant pleural mesothe-
lioma have not been proved to yield a significant sur-
vival advantage.1 Thus there is an urgent need for inves-
tigating new multimodality approaches. In planning
Introduction: Malignant pleural mesothelioma is an ideal model for test-
ing new locoregional multimodality approaches because of its aggressive
local behavior. Methods: This study was planned to investigate the feasi-
bility, safety, and pharmacokinetics of a multimodality therapy includ-
ing an operation, pleural space perfusion (60 minutes) with cisplatin
(100 mg/m2), hyperthermia (41.5°C), and postoperative radiotherapy
(55 Gy to chest wall incisions). The effects of the extent of resection and
perfusion temperature on cisplatin pharmacokinetics were evaluated.
Ten patients with epithelial or mixed, stage I or II, malignant pleural
mesothelioma underwent the following procedures: group A (3
patients), pleurectomy/decortication and normothermic pleural space
antineoplastic perfusion; group B (3 patients), pleurectomy/decortica-
tion and hyperthermic perfusion; and group C (4 patients), pleurop-
neumonectomy and hyperthermic perfusion. Operations were selective-
ly applied depending on tumor extent. Platinum levels were serially
measured by atomic absorption in systemic blood, perfusate, lung, and
endothoracic fascia. Results: The overall procedure was completed in
every case, without any death or toxicity. No lung damage was demon-
strated after treatment. Major complications included 1 wound infec-
tion and 1 diaphragmatic prosthesis displacement. The mean peak plat-
inum plasma levels were reached within 45 to 60 minutes after perfusion
was started. Systemic drug concentrations were greater after pleurecto-
my/decortication than after pleuropneumonectomy (P = .006). The local
tissue/perfusate ratio of platinum concentrations tended to be higher
after hyperthermic perfusion rather than normothermic perfusion.
Conclusion: This multimodality approach is feasible, pharmacokinetical-
ly advantageous, and safe enough to undergo further clinical investiga-
tions. (J Thorac Cardiovasc Surg 1999;117:759-65)
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PLEURAL SPACE PERFUSION WITH CISPLATIN IN THE MULTIMODALITY TREATMENT OF 
MALIGNANT MESOTHELIOMA: A FEASIBILITY AND PHARMACOKINETIC STUDY
operation.7,8 A multimodality approach including an
operation, antineoplastic pleural space perfusion, and
hyperthermia was only applied in 4 patients who under-
went pleurectomy for either malignant mesothelioma
or adenocarcinoma.9 In the present study, such a com-
bined approach was used in patients who had under-
gone either pleurectomy/decortication or pleuropneu-
monectomy for malignant pleural mesothelioma. The
aim of the study was to assess the feasibility and safe-
ty of the overall procedure and the effects of both the
extent of resection and the application of hyperthermia
on the antineoplastic drug pharmacokinetics.
Methods
Patients. Criteria for selection were as follows: (1) diagno-
sis of epithelial or mixed malignant mesothelioma, as demon-
strated by histologic findings, immunohistochemistry, and, in
selected cases, electron microscopy; (2) aged less than 70
years; (3) Eastern Cooperative Oncology Group performance
status less than 1; (4) no previous treatment; (5) cardiac (ejec-
tion fraction > 45%) and pulmonary function (predicted post-
operative forced expiratory volume in 1 second > 1 L) ade-
quate for the planned operation; (6) clinical stages I or II (T1-2
N0); (7) completely resectable tumor, either by pleurecto-
my/decortication or pleuropneumonectomy; (8) adequate
renal, hematologic, and cardiac function; and (9) informed
consent. Complete resectability was predicted according to the
criteria previously outlined by Sugarbaker and colleagues.1,3
Chest wall was preoperatively judged to be invaded if the fat
plane between the parietal pleura and the endothoracic fascia
appeared to be obliterated on computed tomographic (CT)
scans. The protocol was approved by our Institutional Review
Board and by the Ethics Committee of the National Cancer
Institute of Genoa, and all the procedures were carried out in
accordance with the declaration of Helsinki.
Preoperative staging included a CT scan of the chest and
abdomen, a ventilation/perfusion lung scan, a cardiopul-
monary function evaluation, thoracoscopy, and bronchoscopy.
Thoracoscopic incisions were placed in line with the planned
subsequent thoracotomy. Mediastinoscopy was only used
when CT scan showed enlarged (>1 cm) mediastinal nodes.
None of the patients included in the present study had positive
mediastinoscopy.
During the period 1995 to 1997, 10 patients who were
referred with clinically suspected or pathologically diagnosed
malignant mesothelioma were enrolled in the study. Patients
underwent the following procedures: group A (n = 3),
pleurectomy/decortication, normothermic pleural space per-
fusion with cisplatin (100 mg/m2), and postoperative radio-
therapy; group B (n = 3), pleurectomy/decortication, hyper-
thermic (41.5°C) pleural space perfusion with cisplatin (100
mg/m2), and postoperative radiotherapy; group C (n = 4),
pleuropneumonectomy, hyperthermic (41.5°C) pleural space
perfusion with cisplatin (100 mg/m2), and postoperative
radiotherapy. There were 9 male patients and 1 female
patient, ranging in age from 42 to 67 years. The cell type was
epithelial in 4 patients and mixed in 6 patients.
Operation. Because the value of pleuropneumonectomy
with respect to pleurectomy/decortication remains uncer-
tain,10,11 the 2 surgical options were selectively applied on the
basis of lung involvement and patient cardiorespiratory func-
tion. The aim of the operation was to achieve a macroscopi-
cally complete resection, sparing as much apparently normal
lung tissue as possible. Patients scheduled to have pleurecto-
my/decortication were randomly assigned to the normother-
mic or hyperthermic groups.
Before the operation, a thermodilution catheter (Swan-
Ganz; Baxter Healthcare Corp, Edwards Division, Santa Ana,
Calif) was positioned into the pulmonary artery to monitor
hemodynamic changes and central temperature. A posterolat-
eral thoracotomy sparing the serratus anterior muscle, with
subperiosteal resection of the fifth rib, was routinely used.
Whenever lung involvement appeared to be limited, pleurec-
tomy with en bloc minimal wedge resections of the involved
parenchyma and removal of the hemidiaphragm and peri-
cardium was applied. Pleuropneumonectomy included en bloc
resection of the parietal and visceral pleura, lung, ipsilateral
hemidiaphragm, and pericardium.10,12 To accurately dissect
and resect the entire diaphragm, thoracoscopic optics and
instruments were used. In 3 cases in which diaphragm resec-
tion proved to be laborious, a counterincision was associated
to expose the costophrenic sulcus. Previous thoracoscopic
incisions were removed by means of limited chest wall resec-
tions. When the diaphragm was resected, care was taken to
preserve the underlying peritoneum. In the left side, the
diaphragm was always replaced with an expanded polytetra-
fluoroethylene membrane; in the right side, the prosthesis was
applied only when the peritoneum had been withdrawn with
the diaphragm. The pericardium was reconstructed with a
expanded polytetrafluoroethylene prosthetic patch in all cases.
Pleural space perfusion. A standard cisplatin dose (100
mg/m2) with systemic prehydration was used for the known
safety of intrapleural6 and intrapulmonary13 cisplatin and its
reported activity in both pleural14 and peritoneal15 malignant
mesothelioma. No dose escalation was scheduled because
very high local concentrations of platinum were expected even
with standard dosages, whereas lower doses should have
exposed patients to suboptimal drug concentrations. Pleural
space perfusion was begun after the completion of the opera-
tion and meticulous chest wall closure. Inflow chest drains (2
tubes in pleurectomy/decortication and 1 tube in pleuropneu-
monectomy) were positioned at the bottom of the pleural cav-
ity. An additional outflow tube was inserted at the top of the
pleural cavity. The tubes were connected to a perfusion circuit
consisting of polyvinylchloride tubing, a heat exchanger, and
a roller pump. Because a temperature of 44°C to 45°C on the
heat exchanger was selected, the minimal and maximal pleur-
al space perfusion temperatures were maintained between
41.5°C and 42°C. They were monitored with thermoprobes
positioned in the pleural cavity. The body temperature was
continuously checked with an esophageal and a rectal probe.
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No prednisolone for prevention of pulmonary edema was
given.8 The circuits were primed with a mean volume of 4 L,
as previously described.13 The pleural space perfusion flow
was maintained between 200 and 300 mL/min, as monitored
with an electromagnetic flow probe. Chest cavity perfusion
was carried out for 60 minutes. At the end of the perfusion, the
perfusate was discarded. All patients received preventive
antiemetics and were evaluated for toxicity at 12-hour inter-
vals. Approximately 30 days after the treatment, patients
received 55 Gy of radiotherapy to the thoracotomic incision
and sites of chest tubes. As previously described,13 simultane-
ous samples for analysis of platinum concentrations were
drawn from the perfusion circuit and general circulation
before drug administration and at 0, 5, 15, 30, 45, and 60 min-
utes after cisplatin perfusion was started. Systemic blood sam-
ples were also collected at 15 and 30 minutes and at 1, 2, 4, 8,
and 24 hours after the treatment. At the end of the perfusion,
lung parenchyma and endothoracic fascia samples were
obtained for morphologic examination and platinum level
measurements (only fascia samples in the pleuropneumonec-
tomy group). Platinum analysis in fluids and tissues and mor-
phologic evaluations were performed according to methods
previously described in detail.13 The area under the concen-
tration multiplied by the time curve (AUC) from 0 to 60 min-
utes was estimated by the trapezoidal rule. Follow-up evalua-
tion, including high resolution CT scan, lung volume, and
airflow measurements, and determination of pulmonary dif-
fusing capacity and arterial blood gas values were scheduled
at 3, 6, and 12 months after treatment and yearly thereafter.
Results
The operation was completed in every case without
serious complications, and no macroscopic residual dis-
ease was left within the chest at the end of the proce-
dure. During perfusion, the maximum temperature in
the thoracic esophagus did not exceed 38°C, and no
changes in hemodynamic or metabolic parameters and
in blood gas values were found. There was no postoper-
ative death. Major postoperative complications included
1 wound infection and 1 diaphragmatic prosthesis dis-
placement. The last patient required an emergency sec-
ond operation. Drug toxicity, such as nausea, vomiting,
myelosuppression, or neuropathy, did not occur.
Transient postoperative elevation of creatinine values
(maximal level, 1.4 mg/dL) was found in 4 patients.
Total platinum concentrations in the circuit fluid and in
systemic plasma are reported in Fig 1. The data report-
ed in Table I on total systemic and regional exposure to
platinum during perfusion (AUC, 0-60 minutes) and
their mean ratio (AUC regional/AUC systemic values)
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Fig 1. Semilogarithmic plot of systemic and regional (pleural space perfusate). Platinum concentrations versus
time in patients with malignant mesothelioma who underwent pleurectomy/decortication and normothermic
pleural space perfusion with cisplatin (group A; d); pleurectomy/decortication and hyperthermic pleural space
perfusion with cisplatin (group B; n ); pleuropneumonectomy and hyperthermic pleural space perfusion with cis-
platin (group C; s ).
show that systemic absorption of cisplatin from the cir-
cuit was greater in patients undergoing pleurectomy/
decortication (group B) than in those patients who
underwent pleuropneumonectomy (group C); the mean
± SE AUC regional/AUC systemic values were 31.8 ±
8.6 and 87.9 ± 6.2, respectively (P = .006). Moreover,
hyperthermia tended to enhance cisplatin uptake from
the circuit, as suggested by the mean ± SE AUC region-
al/AUC systemic ratio. The relevant values in patients
with pleurectomy/decortication were 49.1 ± 4.6 in nor-
mothermic conditions (group A) versus 31.8 ± 8.6 in
hyperthermic conditions (group B). In the 3 groups of
patients, mean peak platinum plasma levels were
reached within 45 to 60 minutes of drug administration
and tended to be higher in group B (1.00-0.43 m g/mL)
than in group C (0.39-0.10 m g/mL), whereas mean cir-
cuit platinum concentrations were similar (Fig 1). Total
platinum concentrations in lung parenchyma and
endothoracic fascia are reported in Table II. In a previ-
ous experimental study from our laboratory, pigs
received a similar dose of cisplatin intravenously16; plat-
inum concentrations in lung parenchyma of the patients
undergoing pleural space perfusion were nearly 5 times
as high as platinum concentrations in the lung of pigs.
At the end of the 1-hour perfusion, the patient
tissue/patient perfusate ratio tended to be higher in
patients treated with hyperthermic perfusion than in
those patients treated with normothermic perfusion
(group B vs group A). The mean patient lung/patient
perfusate ratio values were 0.35 for group B and 0.25
for group A, respectively. The mean patient endotho-
racic fascia/patient perfusate ratio values were 0.31 and
0.19 for group B and A, respectively. Conversely, the
patient endothoracic fascia/patient perfusate ratio values
were similar in the 2 patient groups who underwent
hyperthermic perfusion, 0.31 for group B and 0.37 for
group C.
Morphologic examination of lung parenchyma
showed no damage as a result of pleural cavity perfu-
sion, either normothermic or hyperthermic (Fig 2).
Electron microscopic examination showed no abnor-
mality of both the alveolar septa and epithelial lining.
Follow-up evaluation did not show significant changes
in the interstitium of treated lungs (Fig 3, A and B). The
post-treatment sequential assessment of respiratory
function parameters demonstrated consistent worsen-
ing in only 3 patients at disease progression.
Discussion
Sugarbaker and colleagues1 have recently empha-
sized the concept that a multimodality approach has the
potential to enhance clinical results of malignant pleur-
al mesothelioma therapy. Because malignant mesothe-
lioma has an aggressive local behavior,1,17 multimodal-
ity regimens should include locoregional treatments
aimed to improve local control.10 Intrapleural drug
instillation has been used either as primary procedure6
or after an operation.4,5,18,19 In both instances, cisplatin
instillation proved to be feasible and well tolerated.
The pharmacokinetics of both cisplatin and mitomycin
have been explored in 12 patients with malignant
mesothelioma who underwent operation and immedi-
ate intrapleural antineoplastic instillation.4 Although
peak plasma levels approximated those attained after
systemic infusion, the peaks were delayed, and a 3- to
5-fold advantage for pleural to plasma AUCs was
found. In 2 further studies, intrapleural cisplatin–based
normothermic chemotherapy (100 mg/m2) was coupled
with an operation.18,19 In both series the treatment
proved feasible and safe, although median survival
remained 11.5 months.
Postoperative antineoplastic pleural space perfusion
gives several theoretic advantages over intrapleural
drug instillation. The latter, if applied without opera-
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Table I. Systemic and regional exposure (AUC) to
total platinum during pleural space perfusion
Group A* Group B† Group C‡
AUC plasma 31.2 ± 5.9 34.6 ± 17.0 14.1 ± 2.9
(m g · min/mL)
AUC regional 1476 ± 181 1036 ± 200 1218 ± 187
(m g · min/mL)
AUC regional/ 49.1 ± 4.6 31.8 ± 8.6 87.9 ± 6.2§
AUC plasma ratio
Values are given as mean ± SE.
*Pleurectomy/decortication (normothermic perfusion). 
†Pleurectomy/decortication (hyperthermic perfusion).
‡Pleuropneumonectomy (hyperthermic perfusion).
§P = .006 (Student t test) versus group B.
Table II. Mean total platinum concentrations in tis-
sues at the end of 1 hour of perfusion
Group A* Group B† Group C‡
Lung (m g Pt/g) 5.15 ± 1.58 5.25 ± 1.50
Endothoracic fascia 3.96 ± 1.34 4.68 ± 1.42 5.24 ± 0.64
(m g Pt/g)
Lung/regional ratio 0.25 ± 0.05 0.35 ± 0.05
Endothoracic fascia/ 0.19 ± 0.04 0.31 ± 0.05 0.37 ± 0.01
regional ratio
Values are given as mean ± SE; µg Pt/g, micrograms platinum per gram of
tissue.
*Pleurectomy/decortication (normothermic perfusion). 
†Pleurectomy/decortication (hyperthermic perfusion).
‡Pleuropneumonectomy (hyperthermic perfusion).
tion, requires a free pleural space and minimal tumor
burden, because drugs penetrate tumor to a distance of
only a few millimeters.14 Intracavitary drug instillation,
if given immediately after the operation, requires
changing the patient’s position every 30 minutes to
achieve good drug distribution throughout the pleural
space. By contrast, perfusion techniques are likely to
minimize the risk of local changes in drug absorption
and, notably, to provide the best means of coupling
chemotherapy and hyperthermia. The application of
hyperthermia in a combined antitumor program seems
to be attractive because of its effectiveness against
malignant cells and its potential to enhance cisplatin
cytotoxicity.9,20 Both preclinical20,21,22 and clinical23
studies showed that hyperthermia significantly increas-
es tumor growth delay by enhancing antineoplastic
drug uptake and cytotoxicity. Intrapleural perfusion
hyperthermic chemotherapy has been used without
pleurectomy in 2 studies7,8 and after pleurectomy in 1
study.9 Perfusions were carried out for time periods
ranging from 60 to 120 minutes; temperature was
maintained between 42°C and 43°C. No major compli-
cations developed, and pharmacokinetic studies
showed that a high concentration of cisplatin was
retained in the pleural cavity during perfusion.
The present study showed that intrapleural perfusion
hyperthermic chemotherapy is technically simple, safe,
and pharmacologically advantageous particularly after
pleuropneumonectomy. Sugarbaker and colleagues12
have already shown that an aggressive multimodality
regimen including pleuropneumonectomy may be
completed with acceptable morbidity and mortality
rates(4.6%); our experience indicated that the associa-
tion of pleuropneumonectomy and hyperthermic pleur-
al space perfusion is feasible and safe. Our pharmaco-
kinetic results may have some implications for the
clinical application of intracavitary chemotherapy. The
first notable finding is the significant plasma concen-
tration of cisplatin after intrapleural administration.
This implies that, because of the great drug absorption
from the pleural space, a highly toxic agent cannot be
proposed for intracavitary administration. Our data are
in agreement with those reported by Rusch and col-
leagues,4 indicating that, after decortication, cisplatin is
rapidly absorbed from the pleural space and reaches
peak plasma concentrations similar to those attained
after intravenous infusion, though substantially
delayed. Perhaps the outstanding finding from our
experience is the more favorable regional to systemic
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 4
Ratto et al   763
Fig 2. Microscopic appearance of normal lung parenchyma
after pleurectomy/decortication followed by 1 hour of hyper-
thermic pleural space perfusion with cisplatin. (Hematoxylin-
eosin stain; original magnification, · 250.)
A
B
Fig 3. CT scan appearance of the lung parenchyma, 3 months
(A) and 12 months (B) after pleurectomy/decortication and
hyperthermic pleural space perfusion with cisplatin.
plasma platinum concentrations in the pleurop-
nemonectomy group than in the pleurectomy/decorti-
cation group. These data support the hypothesis that the
lung plays an important role in cisplatin absorption
from the pleural space. Because the therapeutic pur-
pose is to deliver maximum drug concentrations to
minimum residual tumor, the present study seems to
suggest that pleuropneumonectomy followed by hyper-
thermic antineoplastic pleural space perfusion is the
best multimodality approach. In patients with minimal
visceral pleura involvement who are functionally com-
promised, where pleurectomy/decortication remains
the first choice operation, lung exclusion by clamping
both pulmonary artery and veins during perfusion
could be useful in reducing drug absorption and sys-
temic toxicity.16 Our pharmacokinetic data also seem to
support an enhanced cisplatin uptake from the pleural
space by hyperthermia, because it could be suggested
by the higher ratio between platinum concentrations in
tissues and in the perfusate. Similarly, Formenti and
colleagues24 reported an increased platinum clearance
in patients with ovarian cancer who received intraperi-
toneal carboplatin and hyperthermia.
It could be claimed that a pharmacokinetic advantage
for cisplatin pleural exposure does not necessarily trans-
late into an enhanced delivery of the drug to target tis-
sues. The present study showed that a high concentra-
tion of platinum reached both the lung and the chest
wall fascia, which are the organs potentially involved
with residual tumor. Whether a higher delivery of the
drug to the target organs results in prolonged disease-
free and overall survival remains to be determined. The
evaluation of this point is out of the scope of the present
study. Even literature analysis does not clarify this topic,
because of the lack of randomized trials of adequate
size.
Our morphologic and functional investigations
showed no lung damage from pleural space perfusion.
This is in agreement with the results of Lerza and col-
leagues6 and indicates that the limiting factor in esca-
lating cisplatin doses is systemic toxicity.
In the present series, single-drug chemotherapy has
been used, even though no response greater than 20%
could be expected.25 Unconfirmed data would suggest
that combination chemotherapy including doxorubicin,
cisplatin, bleomycin, and mitomycin might achieve a
response rate as high as 44%.25 Our perfusion tech-
nique may provide the basis for applying potentially
more effective combination chemotherapy.
In conclusion, our results indicate that the combined-
modality regimen that includes an operation and pleur-
al space perfusion with cisplatin and hyperthermia is
feasible, safe, and pharmacokinetically advantageous.
Further advantages of the procedure are its easy techni-
cal application, versatility in associating physical ther-
apies, and suitable temperature control. Because of the
low prevalence of malignant pleural mesothelioma,
multi-institutional prospective trials are required to val-
idate the efficacy of the procedure and to compare dis-
tinct pharmacologic regimens.
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